GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » PS Ratio

Medical Developments International (ASX:MVP) PS Ratio : 1.22 (As of Apr. 07, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Medical Developments International PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medical Developments International's share price is A$0.465. Medical Developments International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.38. Hence, Medical Developments International's PS Ratio for today is 1.22.

The historical rank and industry rank for Medical Developments International's PS Ratio or its related term are showing as below:

ASX:MVP' s PS Ratio Range Over the Past 10 Years
Min: 1.05   Med: 14.96   Max: 34.24
Current: 1.36

During the past 13 years, Medical Developments International's highest PS Ratio was 34.24. The lowest was 1.05. And the median was 14.96.

ASX:MVP's PS Ratio is ranked better than
63.94% of 965 companies
in the Drug Manufacturers industry
Industry Median: 2.07 vs ASX:MVP: 1.36

Medical Developments International's Revenue per Sharefor the six months ended in Dec. 2024 was A$0.18. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.38.

Warning Sign:

Medical Developments International Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Medical Developments International was 0.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 3.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.90% per year.

During the past 13 years, Medical Developments International's highest 3-Year average Revenue per Share Growth Rate was 25.30% per year. The lowest was -6.40% per year. And the median was 7.10% per year.

Back to Basics: PS Ratio


Medical Developments International PS Ratio Historical Data

The historical data trend for Medical Developments International's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medical Developments International PS Ratio Chart

Medical Developments International Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.34 12.19 4.65 2.03 1.05

Medical Developments International Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.03 - 1.05 -

Competitive Comparison of Medical Developments International's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medical Developments International's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's PS Ratio distribution charts can be found below:

* The bar in red indicates where Medical Developments International's PS Ratio falls into.


;
;

Medical Developments International PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Medical Developments International's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.465/0.382
=1.22

Medical Developments International's Share Price of today is A$0.465.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.38.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Medical Developments International  (ASX:MVP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Medical Developments International PS Ratio Related Terms

Thank you for viewing the detailed overview of Medical Developments International's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medical Developments International Business Description

Traded in Other Exchanges
Address
4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International Headlines

From GuruFocus

Roundhill Announces Two Fund Closures

By PRNewswire PRNewswire 03-18-2022